

2021 Annual Spring Meeting of Participants-Virtual Invitation Policy

The 2021 Canadian Cancer Trials Group Annual Spring Meeting of Participants will be held virtually. We have a limited number of attendees that can access the virtual conference platform. In order to have as many people as possible attend so that fruitful discussions can be held, an invitation policy for attendance is in place.

| Invitation Summary |
|---|
| <p>CCTG Committee members of:</p> <ul style="list-style-type: none"> ➤ Disease Site Committee- Chairs, Executives, Liaisons, Members ➤ Disease Site Working Groups , Subcommittees & Disease Oriented Groups- Chairs & Members ➤ IND Committee Chairs (Incoming, Present & Past), Executive & Members ➤ Standing Committee- Chairs, Executives & Members ➤ Former Disease Site Chairs within the past three years |
| <p>Canadian Chairs and Members of -CCTG Led studies, Intergroup studies and Investigational New Drug studies that are Open, Planned, On Hold or Closed (in last six months)</p> <ul style="list-style-type: none"> • CCTG-led studies • Intergroup studies |
| <p>Centre Representatives and Contact Clinical Research Associates from Canadian Member Centres.</p> |
| <p>Centre Nominations for Investigators, New Investigators & CRA's</p> <ul style="list-style-type: none"> ➤ All Member Centres can nominate up to 2 New Investigators ➤ Centres with >5 patients accrued are entitled to nominate one Investigator and one CRA. ➤ Centres with >25 patients accrued are entitled to nominate two Investigators and two CRAs ➤ Centres with >50 patients accrued are entitled to nominate three Investigators and three CRAs |
| <p>Recognition Award Presenters and Recipients</p> |
| <p>Session Speakers</p> |
| <p>Special Guests invited on behalf the Canadian Cancer Trials Group (CCTG's discretion)</p> |
| <p>Pharmaceutical Representatives that Sponsor the Annual Spring Meeting</p> |
| <p>WAITING LIST: If you are eligible to attend the CCTG Annual Spring Meeting (see Registration Policy) please email meeting@ctg.queensu.ca and request to be added to the waiting list. We do not have a mechanism to request an invitation.</p> |

Your Invitations is NON-TRANSFERABLE- you cannot give your invitation with your credentials (name & email address) to another person to attend the 2021 Annual Spring Meeting held online. A confidentiality is to be signed at the time of Registration with your invitation credentials.

INVITATION DETAILS

1. Committee/Trials

Disease Site Committees

Chairs, Executive, Members and Liaisons of the following committees:

- Brain
- Breast
- Gastrointestinal
- Genitourinary
- Gynecologic
- Hematologic
- Lung
- Melanoma
- Sarcoma
- Supportive Care

Standing Committees

Chairs, executive and of the following standing committees:

- Audit and Monitoring Committee (AMC)
- Clinical Trials Committee (CTC)
- Clinical Research Associate Executive Committee (CRAEC)
- Committee on Economic Analysis (CEA)
- Correlative Sciences/Tumour Biology Committee and Executive Committee (CSTB)
- Data Safety Monitoring Committee (DSMC)
- Early Trials Advisory Group (ETAG)
- Patient Representatives (LAYREP)
- Pharmacists Network Steering Group (PHNETSG)
- Quality of Life Committee (QoLC)
- Radiation Oncology Quality Assurance Committee (ROQAC)
- Strategic Executive Advisory Council (SEAC)

Disease Site Committee Working Groups and Subcommittees

Chairs and members of the following committees:

- Breast Disease Site Committee working groups include:
 - Breast~Correlative Sciences/Tumour Biology
- Gastrointestinal Disease Site Committee working groups include:
 - Colon Disease Oriented Group
 - Esophageal Disease Oriented Group
 - Hepatobiliary Disease Oriented Group
 - Neuroendocrine Disease Oriented Group
 - Pancreas Disease Oriented Group
 - Rectal Disease Oriented Group
 - Gastrointestinal ~Correlative Sciences/Tumour Biology Subcommittee
- Gynecology Disease Site Committee working groups include:
 - Cervix Cancer Working Group
 - Endometrial Cancer Working Group
 - Gynecology~Correlative Sciences/Tumour Biology Subcommittee
 - Ovarian Cancer Working Group

- Genitourinary Disease Site Committee working groups include:
 - o Genitourinary~Correlative Sciences/Tumour Biology Subcommittee

- Hematology Disease Site Committee working groups include:
 - o Leukemia Subcommittee
 - o Lymphoma Subcommittee
 - o Myeloma Subcommittee
 - o Hematology~Correlative Sciences/Tumour Biology Subcommittee

- Lung
 - o Lung Correlative Sciences/Tumour Biology Working Group
 - o Mesothelioma/Thymoma/Surgery Working Group
 - o Radiation Oncology Working Group
 - o Small Cell Lung Cancer Working Group

- Head and Neck
 - o Lung Correlative Sciences/Tumour Biology Working Group

- Sarcoma
 - o Sarcoma IND Working Group

Trial Committee Chairs

Canadian Chairs and Members of CCTG Led studies, Intergroup studies and Investigational New Drug studies that are Open, Planned, On Hold or Closed (in last six months)

2. Centre Representatives and Contact Clinical Research Associates

Centre representatives and Contact Clinical Research Associates from member centres.

3. Nominated Investigators and Clinical Research Associates

- All Member Centres can nominate up to 2 New Investigators
- Centres with >5 patients accrued are entitled to nominate one Investigator and one CRA.
- Centres with >25 patients accrued are entitled to nominate two Investigators and two CRAs
- Centres with >50 patients accrued are entitled to nominate three Investigators and three CRAs

4. Nominated New Investigators

- Centres can nominate 2 New Investigators.

A “new” investigator is defined as one who has never attended a CCTG Annual Spring Meeting and is in their first 5 years of staff appointment.

If you have any questions regarding the Invitation Policy please contact meetings@ctg.queensu.ca